Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

21
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
21
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

25
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
25
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

23
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
23
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

27
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
27
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

48
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
48
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

53
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
53

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same author

Power Profiles of an Extended Depth of Focus Contact Lens for Myopia Management.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026
Same author

Outcomes in the treatment of inner ear decompression sickness with hyperbaric oxygen therapy, a systematic review.

Diving and hyperbaric medicine·2026
Same author

Neural responses to acute hypoxia and hyperoxia.

Neuroscience·2026
Same author

Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Application of Physiologically-Based Pharmacokinetic Modeling to Support Drug Labeling: Prediction of CYP3A4-Mediated Pirtobrutinib-Drug Interactions.

CPT: pharmacometrics & systems pharmacology·2025

Related Experiment Video

Updated: May 16, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.2K

A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing

David E Coutant1, Jessica Rehmel2, Donna M Edwards3

  • 1Drug Disposition Department, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, DC0720 46285, USA. cout@lilly.com.

European Journal of Clinical Pharmacology
|April 5, 2025
PubMed
Summary

Inflammation in advanced cancer patients significantly impacts drug metabolism. The neutrophil-to-lymphocyte ratio (NLR) can predict reduced CYP3A4 enzyme activity, crucial for drug clearance.

Keywords:
CYP3A4CancerDisease-drug interactionMidazolamNeutrophil-to-lymphocyte ratioPBPK

More Related Videos

Isolation and Characterization of Neutrophils with Anti-Tumor Properties
10:15

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Published on: June 19, 2015

24.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K

Related Experiment Videos

Last Updated: May 16, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.2K
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
10:15

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Published on: June 19, 2015

24.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • CYP3A4 enzyme activity, responsible for drug metabolism, varies significantly in advanced cancer patients.
  • Inflammation severity, assessed by the neutrophil-to-lymphocyte ratio (NLR), is linked to altered drug pharmacokinetics (PK).

Purpose of the Study:

  • To investigate the relationship between inflammation, indicated by NLR, and CYP3A4 enzyme activity in advanced cancer patients.
  • To quantify the impact of inflammation on the PK of midazolam, a CYP3A4 substrate.

Main Methods:

  • Patients were stratified into high (NLR ≥ 5) and low-to-moderate (NLR < 5) inflammation groups.
  • A physiologically-based pharmacokinetic (PBPK) model was employed to estimate CYP3A4 abundance reductions.
  • Midazolam PK parameters were analyzed to determine group-specific CYP3A4 expression levels.

Main Results:

  • Midazolam clearance (CL/F) was lower in the high inflammation group (20 L/h) compared to the low-to-moderate group (33 L/h).
  • CYP3A4 expression was reduced by approximately 40% in the liver and at least 90% in the gut for the high inflammation group.
  • A 40% reduction in both liver and gut CYP3A4 expression matched PK parameters in the low-to-moderate inflammation group.

Conclusions:

  • The neutrophil-to-lymphocyte ratio (NLR) serves as a reliable inflammatory marker in advanced cancer.
  • NLR correlates with inflammation-driven reductions in CYP3A4 activity, impacting drug metabolism and pharmacokinetics.